{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T22:20:58Z","timestamp":1782080458772,"version":"3.54.5"},"reference-count":36,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      The high-dose methotrexate (HD-MTX) regimen (&gt;1\u2005g\/m\n                      <jats:sup>2<\/jats:sup>\n                      ) is the standard of care for preventing and managing central nervous system (CNS) invasion in diffuse large B-cell lymphoma (DLBCL). Delayed elimination of HD-MTX can lead to severe toxicity. Albumin is a suggested biological marker to predict delayed elimination. This study aims to evaluate whether serum albumin can be used as a predictive factor.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective bicentric study includes DLBCL patients, receiving HD-MTX from 06.30.2016 to 12.31.2023 using CHIMI0v5.9. Data collected included demographic, biological, clinical and therapeutic. Eligible patients were over 18 years, with DLBCL diagnosis, available serum albumin before HD-MTX, with therapeutic drug monitoring of plasma methotrexate available. Univariate and multivariate analysis compared patients with and without delayed elimination.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 68 patients were included, with 15 suffering delayed elimination. Univariate analysis showed that male and Body Surface Area\u2009\u2265\u20092\u2005m\u00b2 (BSA) patients were more likely to have delayed clearance (respectively p\u2009=\u20090.01; p\u2009=\u20090.05). The association with male sex was confirmed in multivariate analysis (p\u2009=\u20090.01). Most cases of hypoalbuminemia were classified as grade 1 or 2. Patients with hypoalbuminemia received lower doses of MTX. Serum albumin level was not significantly associated with delayed elimination (p\u2009=\u20090.8).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Overall, mainly biometric factors are associated with delayed elimination, highlighting the problem of prescribing habits based on body surface area. Albuminemia's role remains debated, and this study does not provide a conclusion, as patients with hypoalbuminemia received lower HD-MTX doses. Studies should account factors related to inflammation, nutrition and specific biomarkers (prealbumin).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552251340000","type":"journal-article","created":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T03:18:36Z","timestamp":1746501516000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Predictive factors for delayed high-dose methotrexate elimination: A practical issue for diffuse large B-cell lymphoma patients"],"prefix":"10.1177","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-7347-7642","authenticated-orcid":false,"given":"Margot","family":"Vattaire-Herv\u00e9","sequence":"first","affiliation":[{"name":"Department of Pharmacy, CHU Reims, F-51100, Reims, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0789-5180","authenticated-orcid":false,"given":"Antoine","family":"Le Bozec","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Universit\u00e9 Paris Saclay, INSERM-S 999, Assistance-Publique - H\u00f4pitaux de Paris, H\u00f4pital Bic\u00eatre, F-91190 Orsay, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8400-2174","authenticated-orcid":false,"given":"Justine","family":"Clarenne","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Universit\u00e9 de Reims Champagne-Ardenne, BIOs, CHU Reims, F-51100, Reims, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Cohet","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Assistance Publique - H\u00f4pitaux de Paris, H\u00f4pital Saint-Louis, F-75010, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Violaine","family":"Lepage","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, CHU Reims, F-51100, Reims, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chlo\u00e9","family":"Gossery","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, CHU Reims, F-51100, Reims, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise","family":"Michelet-Huot","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, CHU Reims, F-51100, Reims, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Quinquenel","sequence":"additional","affiliation":[{"name":"Department of Clinical Hematology, Universit\u00e9 de Reims Champagne-Ardenne, IRMAIC, CHU Reims, F-51100, Reims, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Madelaine","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Assistance Publique - H\u00f4pitaux de Paris, H\u00f4pital Saint-Louis, F-75010, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3463-0089","authenticated-orcid":false,"given":"Eric","family":"Durot","sequence":"additional","affiliation":[{"name":"Department of Clinical Hematology, CHU Reims, F-51100, Reims, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5139-7034","authenticated-orcid":false,"given":"Florian","family":"Slimano","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Universit\u00e9 de Reims Champagne-Ardenne, BioSpecT, CHU Reims, F-51100, Reims, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,5,6]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2027612"},{"key":"e_1_3_2_3_2","first-page":"5","article-title":"Epidemiology of non-Hodgkin\u2019s lymphoma","volume":"9","author":"Thandra KC","year":"2021","unstructured":"Thandra KC, Barsouk A, Saginala K, et al. Epidemiology of non-Hodgkin\u2019s lymphoma. Med Sci 2021; 9: 5.","journal-title":"Med Sci"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00371-0"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014506"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023020168"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0243"},{"key":"e_1_3_2_8_2","unstructured":"R\u00e9sum\u00e9 des caract\u00e9ristiques du produit - METHOTREXATE ACCORD 25\u2005mg\/ml solution injectable- Base de donn\u00e9es publique des m\u00e9dicaments."},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.11-6-694"},{"key":"e_1_3_2_10_2","first-page":"677","article-title":"The loading rate determines tumor targeting properties of methotrexate-albumin conjugates in rats","volume":"8","author":"Stehle G","year":"1997","unstructured":"Stehle G, Sinn H, Wunder A, et al. The loading rate determines tumor targeting properties of methotrexate-albumin conjugates in rats. Anti-Cancer Drugs 1997; 8: 677\u2013685.","journal-title":"Anti-Cancer Drugs"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1507547"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2015-0164"},{"key":"e_1_3_2_13_2","unstructured":"INCA (Institut National du cancer) Mesures de pr\u00e9vention et de gestion de la toxicit\u00e9 r\u00e9nale induite par le m\u00e9thotrexate haute-dose. jul 2023. 978-2-38559-014-7."},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-016-2795-7"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1177\/1060028021992767"},{"key":"e_1_3_2_16_2","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE). 2017."},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1586\/ecp.11.57"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2022.02.007"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.2515\/therapie\/2010016"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2479"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.840780"},{"key":"e_1_3_2_22_2","unstructured":"Soldin O. Sex Differences in Pharmacokinetics and Pharmacodynamics. 2013."},{"key":"e_1_3_2_23_2","first-page":"3","article-title":"Effect of serum albumin level on high-dose methotrexate induced toxicities in acute lymphoblastic leukemia patients","volume":"17","author":"Mirza MA","year":"2023","unstructured":"Mirza MA, Aruna D, Konatam ML. Effect of serum albumin level on high-dose methotrexate induced toxicities in acute lymphoblastic leukemia patients. Int J Health Sci 2023; 17: 3\u20139.","journal-title":"Int J Health Sci"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-023-03579-0"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1177\/0148607191015002207"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nupar.2012.12.003"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afy169"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1177\/0884533616680354"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2021.620696"},{"key":"e_1_3_2_30_2","first-page":"853","article-title":"The use of body surface area as a criterion of drug dosage in cancer chemotherapy","volume":"18","author":"Pinkel D","year":"1958","unstructured":"Pinkel D. The use of body surface area as a criterion of drug dosage in cancer chemotherapy. Cancer Res 1958; 18: 853\u2013856.","journal-title":"Cancer Res"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bulcan.2016.04.002"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/jpen.1451"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/bdd.565"},{"key":"e_1_3_2_34_2","unstructured":"Jones K Mohassel L Cuevo R. Evaluation of a Pharmacist-Driven High-Dose MTX Monitoring Protocol. 2024;14(1)."},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27167"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1957"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13600"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552251340000","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552251340000","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552251340000","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:31:07Z","timestamp":1777689067000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552251340000"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,6]]},"references-count":36,"alternative-id":["10.1177\/10781552251340000"],"URL":"https:\/\/doi.org\/10.1177\/10781552251340000","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,6]]},"article-number":"10781552251340000"}}